Kinetics：TAKE2 PROPHECY™ Nasopharyngeal Carcinoma (NPC) DNA Screening

TAKE2 PROPHECY™
Nasopharyngeal Carcinoma (NPC) DNA Screening

「Nasopharyngeal Carcinoma (NPC) is a type of head and neck cancer and it is one of the top ten cancer killers in Hong Kong. It has a particularly high incidence in Southeast Asia, especially in Guangdong and Guangxi in Mainland China and in Hong Kong, it’s known as the “Cantonese Cancer”.

Symptoms: nosebleed, headache and ringing in the ears

Many patients do not have any signs or symptoms until NPC reaches an advanced stage. Historical data shows that approximately 80% of unscreened patients are diagnosed with advanced NPC. Late-stage NPC is more difficult to treat than early-stage NPC and the survival rate within 5 years could be less than 60%.

Currently, there is no vaccination for the prevention of NPC as a type of virus-associated cancer. Early cancer screening is the one of the ways to secure a significantly better prognosis as it can help identifying asymptomatic NPC at a significantly earlier stage, which allows early interventions and treatments that greatly increase the chance of successful treatment and better prognosis.

Uniqueness and Advantages of the Prophecy™ test for NPC:

Invented by a world-class research team of the Chinese University of Hong Kong.
Clinically proven for detection of NPC among asymptomatic individuals.
High accuracy (>97% sensitivity)
Low false-positive rate at 0.7% (false-positive rate of EBV test: 40%)
Non-invasive (only blood sample is required)
Enables early diagnosis, and hence results in a better prognosis. 97% of the patients have a survival rate within 3 years.

Nasopharyngeal Carcinoma (NPC) DNA Screening